PDS Biotechnology (NASDAQ:PDSB) Cut to Sell at Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

PDSB has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a report on Wednesday, April 15th. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Trading Down 2.7%

Shares of PDSB opened at $0.68 on Friday. The firm has a market capitalization of $38.11 million, a price-to-earnings ratio of -1.02 and a beta of 1.59. The company has a debt-to-equity ratio of 2.73, a current ratio of 2.26 and a quick ratio of 2.26. PDS Biotechnology has a 1-year low of $0.51 and a 1-year high of $1.55. The company has a 50-day moving average of $0.94 and a 200 day moving average of $0.89.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, May 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. On average, research analysts expect that PDS Biotechnology will post -0.52 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

A number of large investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in shares of PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after purchasing an additional 44,100 shares in the last quarter. Virtu Financial LLC acquired a new stake in PDS Biotechnology in the fourth quarter worth about $25,000. Armistice Capital LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth about $2,182,000. Commonwealth Equity Services LLC increased its holdings in shares of PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after acquiring an additional 106,300 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after purchasing an additional 38,399 shares during the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.